Abcuro
Last verified 2026-05-13. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $300.0Mattributed |
|---|---|
| Latest round | series-c, $200.0M, 2025-02-12attributed |
| Founded | 2018 |
| Headquarters | Newton |
| Industry | biotech |
| Stage | series-b+ |
| Website | abcuro.com |
Abcuro develops monoclonal antibodies that selectively deplete highly cytotoxic T and NK cells driving autoimmune disease and cancer. It targets patients with conditions such as inclusion body myositis and T/NK-cell lymphomas. Its lead antibody ulviprubart, now in late-stage trials, is built around precise KLRG1 targeting.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-02-12 | series-c | $200.0M | nea |
Detected tech stack
PHP 7.4.33, WordPress 5.9.3, Apache HTTP Server, Yoast SEO 18.2, Genesis theme, jQuery Migrate 3.3.2, MySQL, jquery 3.6.0, apache
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series C, $200.0M | attributed | vc-portfolio named as publisher. No document URL on file. |
| Total raised $300.0M | attributed | vc-portfolio named as publisher. No document URL on file. |
| Company existence | self-reported | abcuro.com, read 2026-05-13 |
| Description | self-reported | abcuro.com, read 2026-05-13 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.